Idec Pharmaceuticals Corp. (Delaware)
Records under this name other than patents Idec Pharmaceuticals Corp. (Delaware) holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 8 of 8 · Back to Idec Pharmaceuticals Corp. (Delaware)
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,682,734 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Formerly held Term ended Ended no later than Jan 27, 2021 · USPTO record | Term ended | Ended no later than Jan 27, 2021 | USPTO record |
| US 7,744,877 | Expression and use of anti-CD20 Antibodies Formerly held Term ended Term ended Jun 21, 2019 · USPTO record | Term ended | Term ended Jun 21, 2019 | USPTO record |
| US 6,399,061 | Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma Formerly held Term ended Term ended Jun 4, 2019 · USPTO record | Term ended | Term ended Jun 4, 2019 | USPTO record |
| US 7,381,560 | Expression and use of anti-CD20 antibodies Formerly held Term ended Term ended Sep 22, 2016 · USPTO record | Term ended | Term ended Sep 22, 2016 | USPTO record |
| US 7,422,739 | Anti-CD20 antibodies Formerly held Term ended Term ended Sep 3, 2015 · USPTO record | Term ended | Term ended Sep 3, 2015 | USPTO record |
| US 5,736,137 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Formerly held Term ended Term ended no later than Apr 7, 2018 · Low confidence | Term ended | Term ended no later than Apr 7, 2018 | Low confidence |
| US 5,776,456 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Formerly held Term ended Term ended no later than Jul 7, 2018 · Low confidence | Term ended | Term ended no later than Jul 7, 2018 | Low confidence |
| US 5,843,439 | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma Formerly held Term ended Term ended no later than Dec 1, 2018 · Low confidence | Term ended | Term ended no later than Dec 1, 2018 | Low confidence |